Search

Your search keyword '"Kostic, Ana"' showing total 247 results

Search Constraints

Start Over You searched for: "Kostic, Ana" Remove constraint "Kostic, Ana"
247 results on '"Kostic, Ana"'

Search Results

2. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.

3. Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer’s disease

5. The ReAct project: Analysis of data from 23 different laboratories to characterise DNA recovery given two sets of activity level propositions

6. MULTIFACTORIAL ETIOLOGY OF ATIPICAL HEMOLYTIC UREMIC SYNDROME-CASE REPORT

7. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

11. An open-label study evaluating the safety, behavioral, and electrophysiological outcomes of low-dose ketamine in children with ADNP syndrome

14. Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

15. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

16. Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001

17. Prospective and detailed behavioral phenotyping in DDX3X syndrome

20. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study

24. POSTER: CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

25. CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

26. MCL-096 Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

27. POSTER: MCL-096 Lisocabtagene Maraleucel (Liso-Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single-Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

28. P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS

29. A Test Facility to Investigate Sheath Effects during Ion Cyclotron Resonance Heating

33. Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

39. Additional file 1 of Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

43. Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

46. Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

47. Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer’s disease

48. Recent progress on improving ICRF coupling and reducing RF-specific impurities in ASDEX Upgrade

49. Feasibility study of Passive Optical Emission Spectroscopy for the electric field measurements in IShTAR

50. IShTAR ICRF antenna field characterization in vacuum and plasma by using probe diagnostic

Catalog

Books, media, physical & digital resources